期刊
REGENERATIVE MEDICINE
卷 10, 期 1, 页码 49-64出版社
FUTURE MEDICINE LTD
DOI: 10.2217/RME.14.73
关键词
bioreactor; cell-based therapy; clinical trials; manufacture; MSC; regenerative medicine; stem cell; translation
资金
- Engineering and Physical Sciences Research Council
- FUJIFILM Diosynth Biotechnologies
Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据